With a market cap of $18 billion, Moderna is at the forefront of innovative healthcare solutions, pioneering treatments for ...

CRDMO capabilities are tailored for a full range of mRNA applications, including small-scale quantities for personalized ...

Australia’s audit office will probe the Morrison government’s $2 billion deal with US pharmaceutical giant Moderna to set up ...

Yes, you can get your flu and COVID-19 shots at the same time. Don't call them boosters — they're not just another dose of ...

We initiated our '24-'25 COVID-19 commercial season in mid-September shortly after achieving ... Novavax is demonstrating the ability to compete with the mRNA vaccines. In one regional supplier of ...

(Reuters) -Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ...

Novavax’s COVID-19 vaccine won FDA approval in October 2023. It’s different from the mRNA vaccines developed by Pfizer Inc.

There is no evidence Japan has named the COVID-19 vaccine the “most deadly drug in history,” as the post claims.

Reactogenicity is comparable for simultaneous and sequential administration of mRNA COVID-19 and influenza vaccines.

CAMBRIDGE, MA / ACCESSWIRE / November 12, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in ...

Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...